Inhibition of the progesterone nuclear receptor during the bone linear growth phase increases peak bone mass in female mice

PLoS ONE

Volumn 5, Issue 7, 2010, Pages

  Yao, Wei ^a   Dai, Weiwei ^a   Shahnazari, Mohammad ^a   Pham, Aaron ^a   Chen, Zhiqiang ^a   Chen, Haiyan ^a   Guan, Min ^a   Lane, Nancy E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS RECEPTOR; ESTROGEN; FOLLITROPIN; INHIBIN A; MIFEPRISTONE; PROGESTERONE; PROGESTERONE RECEPTOR; HORMONE ANTAGONIST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE GROWTH; BONE MASS; CANCELLOUS BONE; CELL MATURATION; CONTROLLED STUDY; CORTICAL BONE; FEMALE; GENE EXPRESSION REGULATION; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; OSSIFICATION; OSTEOCLAST ACTIVITY; OSTEOLYSIS; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; SEX DIFFERENCE; SIGNAL TRANSDUCTION; STRAIN DIFFERENCE; UPREGULATION; WILD TYPE; ANIMAL; APOPTOSIS; BONE DENSITY; BONE DEVELOPMENT; CELL CULTURE; CELL DIFFERENTIATION; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; MOUSE MUTANT; OSTEOBLAST; PHYSIOLOGY;

MUS;

ANIMALS; APOPTOSIS; BODY WEIGHT; BONE DENSITY; BONE DEVELOPMENT; BONE RESORPTION; CELL DIFFERENTIATION; CELLS, CULTURED; FEMALE; HORMONE ANTAGONISTS; MALE; MICE; MICE, KNOCKOUT; MIFEPRISTONE; OSTEOBLASTS; OSTEOGENESIS; RECEPTORS, PROGESTERONE; SEX FACTORS;

EID: 77955408321     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011410     Document Type: Article

References (97)

1. Peacock M, Turner CH, Econs MJ, Foroud T (2002) Genetics of osteoporosis. Endocr Rev 23: 303-326.
2. Johnston CC, Jr., Slemenda CW (1993) Determinants of peak bone mass. Osteoporos Int 3 Suppl 1: 54-55.
3. Bonjour JP, Chevalley T, Ammann P, Slosman D, Rizzoli R (2001) Gain in bone mineral mass in prepubertal girls 3.5 years after discontinuation of calcium supplementation: a follow-up study. Lancet 358: 1208-1212.
4. Ward KA, Roberts SA, Adams JE, Lanham-New S, Mughal MZ (2007) Calcium supplementation and weight bearing physical activity-do they have a combined effect on the bone density of pre-pubertal children? Bone 41: 496-504.
5. Matkovic V, Goel PK, Badenhop-Stevens NE, Landoll JD, Li B, et al. (2005) Calcium supplementation and bone mineral density in females from childhood to young adulthood: a randomized controlled trial. Am J Clin Nutr 81: 175-188.
6. Courteix D, Jaffre C, Lespessailles E, Benhamou L (2005) Cumulative effects of calcium supplementation and physical activity on bone accretion in premenar-chal children: a double-blind randomised placebo-controlled trial. Int J Sports Med 26: 332-338.
7. Azizi G, Hansen A, Prestwood KM (2003) Effect ofmicronized progesterone on bone turnover in postmenopausal women on estrogen replacement therapy. Endocr Res 29: 133-140.
8. Liu JH, Muse KN (2005) The effects of progestins on bone density and bone metabolism in postmenopausal women: a randomized controlled trial. Am J Obstet Gynecol 192: 1316-1323; discussion 1323-1314.
9. Petitti DB, Piaggio G, Mehta S, Cravioto MC, Meirik O (2000) Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. The WHO Study of Hormonal Contraception and Bone Health. Obstet Gynecol 95: 736-744.
10. Bachrach LK, Cundy T, Ott SM (2000) Depot medroxyprogesterone acetate in teens: A risk for bone health? Pediatrics 106: 1137-1138.
11. Cundy T, Cornish J, Roberts H, Elder H, Reid IR (1998) Spinal bone density in women using depot medroxyprogesterone contraception. Obstet Gynecol 92: 569-573.
12. Cundy T, Reid IR (1997) Bone loss and depot medroxyprogesterone. Am J Obstet Gynecol 176: 1116-1117.
13. Cundy T, Farquhar CM, Cornish J, Reid IR (1996) Short-term effects of high dose oral medroxyprogesterone acetate on bone density in premenopausal women. J Clin Endocrinol Metab 81: 1014-1017.
14. Cundy T, Evans M, Roberts H, Wattie D, Ames R, et al. (1991) Bone density in women receiving depot medroxyprogesterone acetate for contraception. Bmj 303: 13-16.
15. Cromer BA, Scholes D, Berenson A, Cundy T, Clark MK, et al. (2006) Depot medroxyprogesterone acetate and bone mineral density in adolescents-the Black Box Warning: a Position Paper of the Society for Adolescent Medicine. J Adolesc Health 39: 296-301.
16. Horowitz M, Wishart JM, Need AG, Morris HA, Nordin BE (1993) Effects of norethisterone on bone related biochemical variables and forearm bone mineral in post-menopausal osteoporosis. Clin Endocrinol (Oxf) 39: 649-655.
17. Gallagher JC, Kable WT, Goldgar D (1991) Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen. Am J Med 90: 171-178.
18. Prior JC, Vigna YM, Barr SI, Rexworthy C, Lentle BC (1994) Cyclic medroxyprogesterone treatment increases bone density: a controlled trial in active women with menstrual cycle disturbances. Am JMed 96: 521-530.
19. Kalu DN, Salerno E, Liu CC, Echon R, Ray M, et al. (1991) A comparative study of the actions of tamoxifen, estrogen and progesterone in the ovariectomized rat. Bone Miner 15: 109-123.
20. Barengolts EI, Gajardo HF, Rosol TJ, D'AnzaJJ, Pena M, et al. (1990) Effects of progesterone on postovariectomy bone loss in aged rats. J Bone Miner Res 5: 1143-1147.
21. Wei LL, Leach MW, Miner RS, Demers LM (1993) Evidence for progesterone receptors in human osteoblast-like cells. Biochem Biophys Res Commun 195: 525-532.
22. MacNamara P, O'Shaughnessy C, Manduca P, Loughrey HC (1995) Progesterone receptors are expressed in human osteoblast-like cell lines and in primary human osteoblast cultures. Calcif Tissue Int 57: 436-441.
23. Mac Namara P, Loughrey HC (1998) Progesterone receptor A and B isoform expression in human osteoblasts. Calcif Tissue Int 63: 39-46.
24. Pensler JM, Radosevich JA, Higbee R, Langman CB (1990) Osteoclasts isolated from membranous bone in children exhibit nuclear estrogen and progesterone receptors. JBone Miner Res 5: 797-802.
25. Rickard DJ, Iwaniec UT, Evans G, Hefferan TE, Hunter JC, et al. (2008) Bone growth and turnover in progesterone receptor knockout mice. Endocrinology 149: 2383-2390.
26. Barengolts EI, Lathon PV, Lindh FG (1995) Progesterone antagonist RU 486 has bone-sparing effects in ovariectomized rats. Bone 17: 21-25.
27. Abe T, Chow JW, Lean JM, Chambers TJ(1992) The progesterone antagonist, RU486 does not affect basal or estrogen-stimulated cancellous bone formation in the rat. Bone Miner 19: 225-233.
28. Schneider JS, Stone MK, Wynne-Edwards KE, Horton TH, Lydon J, et al. (2003) Progesterone receptors mediate male aggression toward infants. Proc Natl Acad Sci U S A 100: 2951-2956.
29. Schneider JS, Burgess C, Sleiter NC, DonCarlos LL, Lydon JP, et al. (2005) Enhanced sexual behaviors and androgen receptor immunoreactivity in the male progesterone receptor knockout mouse. Endocrinology 146: 4340-4348.
30. Conneely OM, Mulac-Jericevic B, Lydon JP, De Mayo FJ(2001) Reproductive functions of the progesterone receptor isoforms: lessons from knock-out mice. Mol Cell Endocrinol 179: 97-103.
31. Chappell PE, Schneider JS, Kim P, Xu M, Lydon JP, et al. (1999) Absence of gonadotropin surges and gonadotropin-releasing hormone self-priming in ovariectomized (OVX), estrogen (E2)-treated, progesterone receptor knockout (PRKO) mice. Endocrinology 140: 3653-3658.
32. Chappell PE, Lydon JP, Conneely OM, O'Malley BW, Levine JE (1997) Endocrine defects in mice carrying a null mutation for the progesterone receptor gene. Endocrinology 138: 4147-4152.
33. Halloran BP, Ferguson VL, Simske SJ, Burghardt A, Venton LL, et al. (2002) Changes in bone structure and mass with advancing age in the male C57BL/6 J mouse. JBone Miner Res 17: 1044-1050.
34. Ferguson VL, Ayers RA, Bateman TA, Simske SJ(2003) Bone development and age-related bone loss in male C57BL/6Jmice. Bone 33: 387-398.
35. Scheven BA, Damen CA, Hamilton NJ, Verhaar HJ, Duursma SA (1992) Stimulatory effects of estrogen and progesterone on proliferation and differentiation of normal human osteoblast-like cells in vitro. Biochem Biophys Res Commun 186: 54-60.
36. Slootweg M C, Ederveen A G, Schot L P,Schoonen W G, Kloosterboer H J(1992) Oestrogen and progestogen synergistically stimulate human and rat osteoblast proliferation. J Endocrinol 133: R5-8.
37. Ishida Y, Tertinegg I, Heersche JN (1996) Progesterone and dexamethasone stimulate proliferation and differentiation of osteoprogenitors and progenitors for adipocytes and macrophages in cell populations derived from adult rat vertebrae. JBone Miner Res 11: 921-930.
38. Chen L, Foged NT (1997) Induction ofosteocalcin gene expression in vitro by progesterone. JTongji Med Univ 17: 72-74.
39. Ishida Y, Bellows CG, Tertinegg I, Heersche JN (1997) Progesterone-mediated stimulation of osteoprogenitor proliferation and differentiation in cell populations derived from adult or fetal rat bone tissue depends on the serum component of the culture media. Osteoporos Int 7: 323-330.
40. Ishida Y, Heersche JN (1997) Progesterone stimulates proliferation and differentiation of osteoprogenitor cells in bone cell populations derived from adult female but not from adult male rats. Bone 20: 17-25.
41. Liang M, Liao EY, Xu X, Luo XH, Xiao XH (2003) Effects ofprogesterone and 18-methyl levonorgestrel on osteoblastic cells. Endocr Res 29: 483-501.
42. Wang QP, Xie H, Yuan LQ, Luo XH, Li H, et al. (2008) Effect of progesterone on apoptosis of murine MC3T3-E1 osteoblastic cells. Amino Acids.
43. Lydon JP, DeMayo FJ, Funk CR, Mani SK, Hughes AR, et al. (1995) Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev 9: 2266-2278.
44. Turgeon JL, Waring DW (2001) Luteinizing hormone secretion from wild-type and progesterone receptor knockout mouse anterior pituitary cells. Endocrinology 142: 3108-3115.
45. Wang JD, Shi WL, Zhang GQ, Bai XM (1994) Tissue and serum levels of steroid hormones and RU 486 after administration of mifepristone. Contraception 49: 245-253.
46. Sanchez-Criado JE, Uilenbroek JT, de Jong FH (1992) Antiprogesterone RU486 increases serum immunoreactive inhibin levels and LH:FSH and testoster-one:oestradiol ratios in cyclic rats. JEndocrinol 134: 51-57.
47. Sanchez-Criado JE, Bellido C, Lopez FJ, Galiot F (1992) Antiprogesterone RU486 induces dissociation of LH and FSH secretion in the cyclic rat: effect of anti-inhibin serum. J Endocrinol 134: 43-49.
48. Danilovich N, Babu PS, Xing W, Gerdes M, Krishnamurthy H, et al. (2000) Estrogen deficiency, obesity, and skeletal abnormalities in follicle-stimulating hormone receptor knockout (FORKO) female mice. Endocrinology 141: 4295-4308.
49. Iqbal J, Sun L, Kumar TR, Blair HC, Zaidi M (2006) Follicle-stimulating hormone stimulates TNF production from immune cells to enhance osteoblast and osteoclast formation. Proc Natl Acad Sci U S A 103: 14925-14930.
50. Burger HG, Cahir N, Robertson DM, Groome NP, Dudley E, et al. (1998) Serum inhibins A and B fall differentially as FSH rises in perimenopausal women. Clin Endocrinol (Oxf) 48: 809-813.
51. Meehan T, Schlatt S, O'Bryan MK, de Kretser DM, Loveland KL (2000) Regulation of germ cell and Sertoli cell development by activin, follistatin, and FSH. Dev Biol 220: 225-237.
52. de Kretser DM, Meinhardt A, Meehan T, Phillips DJ, O'Bryan MK, et al. (2000) The roles of inhibin and related peptides in gonadal function. Mol Cell Endocrinol 161: 43-46.
53. de Kretser DM, Loveland KL, Meehan T, O'Bryan MK, Phillips DJ, et al. (2001) Inhibins, activins and follistatin: actions on the testis. Mol Cell Endocrinol 180: 87-92.
54. Crofton PM, Illingworth PJ, Groome NP, Stirling HF, Swanston I, et al. (1997) Changes in dimeric inhibin A and B during normal early puberty in boys and girls. Clin Endocrinol (Oxf) 46: 109-114.
55. Welt CK, McNicholl DJ, Taylor AE, HallJE (1999) Female reproductive aging is marked by decreased secretion of dimeric inhibin. J Clin Endocrinol Metab 84: 105-111.
56. Perrien DS, Akel NS, Edwards PK, Carver AA, Bendre MS, et al. (2007) Inhibin A is an endocrine stimulator of bone mass and strength. Endocrinology 148: 1654-1665.
57. Essers MA, Weijzen S, de Vries-Smits AM, Saarloos I, de Ruiter ND, et al. (2004) FOXO transcription factor activation by oxidative stress mediated by the small GTPase Ral and JNK. Embo J23: 4802-4812.
58. Matsumoto M, Accili D (2005) All roads lead to FoxO. Cell Metab 1: 215-216.
59. Greer EL, Brunet A (2008) FOXO transcription factors in ageing and cancer. Acta Physiol (Oxf) 192: 19-28.
60. Greer EL, Brunet A (2005) FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24: 7410-7425.
61. Manolagas SC, Kousteni S, Jilka RL (2002) Sex steroids and bone. Recent Prog Horm Res 57: 385-409.
62. Razmara A, Duckles SP, Krause DN, Procaccio V (2007) Estrogen suppresses brain mitochondrial oxidative stress in female and male rats. Brain Res 1176: 71-81.
63. Grassi F, Tell G, Robbie-Ryan M, Gao Y, Terauchi M, et al. (2007) Oxidative stress causes bone loss in estrogen-deficient mice through enhanced bone marrow dendritic cell activation. Proc Natl Acad Sci U S A 104: 15087-15092.
64. Stirone C, Duckles SP, Krause DN, Procaccio V (2005) Estrogen increases mitochondrial efficiency and reduces oxidative stress in cerebral blood vessels. Mol Pharmacol 68: 959-965.
65. Sur P, Sribnick EA, Wingrave JM, Nowak MW, Ray SK, et al. (2003) Estrogen attenuates oxidative stress-induced apoptosis in C6 glial cells. Brain Res 971: 178-188.
66. Abplanalp W, Ravi Subbiah MT (2001) Uptake and protection against oxidative stress by estrogen esters in THP-1 human macrophage cell lines. Gynecol Obste Invest 51: 81-84.
67. Sudoh N, Toba K, Akishita M, Ako J, Hashimoto M, et al. (2001) Estrogen prevents oxidative stress-induced endothelial cell apoptosis in rats. Circulation 103: 724-729.
68. Lengyel F, Vertes Z, Kovacs KA, Kornyei JL, Sumegi B, et al. (2007) Effect of estrogen and inhibition of phosphatidylinositol-3 kinase on Akt and FOXO1 in rat uterus. Steroids 72: 422-428.
69. Ward EC, Hoekstra AV, Blok LJ, Hanifi-Moghaddam P, Lurain JR, et al. (2008) The regulation and function of the forkhead transcription factor, Forkhead box O1, is dependent on the progesterone receptor in endometrial carcinoma. Endocrinology 149: 1942-1950.
70. Takano M, Lu Z, Goto T, Fusi L, Higham J, et al. (2007) Transcriptional cross talk between the forkhead transcription factor forkhead box O1A and the progesterone receptor coordinates cell cycle regulation and differentiation in human endometrial stromal cells. Mol Endocrinol 21: 2334-2349.
71. Labied S, Kajihara T, Madureira PA, Fusi L,Jones MC, et al. (2006) Progestins regulate the expression and activity of the forkhead transcription factor FOXO1 in differentiating human endometrium. Mol Endocrinol 20: 35-44.
72. Brosens JJ, Gellersen B (2006) Death or survival-progesterone-dependent cell fate decisions in the human endometrial stroma. J Mol Endocrinol 36: 389-398.
73. Krum SA, Miranda-Carboni GA, Hauschka PV, Carroll JS, Lane TF, et al. (2008) Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. EMBO J27: 535-545.
74. Li P, Lee H, Guo S, Unterman TG, Jenster G, et al. (2003) AKT-independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR. Mol Cell Biol 23: 104-118.
75. Fan W, Yanase T, Morinaga H, Okabe T, Nomura M, et al. (2007) Insulin-like growth factor 1/insulin signaling activates androgen signaling through direct interactions of Foxo1 with androgen receptor. JBiol Chem 282: 7329-7338.
76. Huang H, Muddiman DC, Tindall DJ (2004) Androgens negatively regulate forkhead transcription factor FKHR (FOXO1) through a proteolytic mechanism in prostate cancer cells. JBiol Chem 279: 13866-13877.
77. Boonyaratanakornkit V, McGowan E, Sherman L, Mancini MA, Cheskis BJ, et al. (2007) The role ofextranuclear signaling actions ofprogesterone receptor in mediating progesterone regulation of gene expression and the cell cycle. Mol Endocrinol 21: 359-375.
78. Boonyaratanakornkit V, Edwards DP (2007) Receptor mechanisms mediating non-genomic actions of sex steroids. Semin Reprod Med 25: 139-153.
79. Roemer SC, Adelman J, Churchill ME, Edwards DP(2008)Mechanism of high mobility group protein B enhancement of progesterone receptor sequence-specific DNA binding. Nucleic Acids Res 36: 3655-3666.
80. Boonyaratanakornkit V, Bi Y, Rudd M, Edwards DP (2008) The role and mechanism of progesterone receptor activation of extra-nuclear signaling pathways in regulating gene transcription and cell cycle progression. Steroids 73: 922-928.
81. Gellersen B, Fernandes MS, Brosens JJ (2009) Non-genomic progesterone actions in female reproduction. Hum Reprod Update 15: 119-138.
82. Rohe HJ, Ahmed IS, Twist KE, Craven RJ (2009) PGRMC1 (progesterone receptor membrane component 1): A targetable protein with multiple functions in steroid signaling, P450 activation and drug binding. Pharmacol Ther 121: 14-19.
83. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, et al. (1999) Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. JClin Invest 104: 1363-1374.
84. Martin GS (2001) The hunting ofthe Src. Nat Rev Mol Cell Biol2: 467-475.
85. Marzia M, Sims NA, Voit S, Migliaccio S, Taranta A, et al. (2000) Decreased c-Src expression enhances osteoblast differentiation and bone formation. J Cell Biol 151: 311-320.
86. Grosse B, Kachkache M, Le Mellay V, Lieberherr M (2000) Membrane signalling and progesterone in female and male osteoblasts. I. Involvement Of intracellular Ca(2+), inositol trisphosphate, and diacylglycerol, but not cAMP. J Cell Biochem 79: 334-345.
87. Le Mellay V, Lieberherr M (2000) Membrane signaling and progesterone in female and male osteoblasts. II. Direct involvement ofG alpha q/11 coupled to PLC-beta 1 and PLC-beta 3. J Cell Biochem 79: 173-181.
88. Hsiao EC, Boudignon BM, Chang WC, Bencsik M, Peng J, et al. (2008) Osteoblast expression of an engineered Gs-coupled receptor dramatically increases bone mass. Proc Natl Acad Sci U S A.
89. Reddy DS, O'Malley BW, Rogawski MA (2005) Anxiolytic activity of progesterone in progesterone receptor knockout mice. Neuropharmacology 48: 14-24.
90. Frye CA, Sumida K, LydonJP, O'Malley BW, Pfaff DW (2006) Mid-aged and aged wild-type and progestin receptor knockout (PRKO) mice demonstrate rapid progesterone and 3alpha,5alpha-THP-facilitated lordosis. Psychopharmacology (Berl) 185: 423-432.
91. Brouwers JE, van Rietbergen B, Huiskes R (2007) No effects ofin vivo micro-CT radiation on structural parameters and bone marrow cells in proximal tibia of wistar rats detected after eight weekly scans. J Orthop Res 25: 1325-1332.
92. Yao W, Hadi T, Jiang Y, Lotz J, Wronski TJ, et al. (2005) Basic fibroblast growth factor improves trabecular bone connectivity and bone strength in the lumbar vertebral body of osteopenic rats. Osteoporos Int 16: 1939-1947.
93. Lane NE, Yao W, Nakamura MC, Humphrey MB, Kimmel D, et al. (2005) Mice lacking the integrin beta5 subunit have accelerated osteoclast maturation and increased activity in the estrogen-deficient state. J Bone Miner Res 20: 58-66.
94. Lane NE, Yao W, Balooch M, Nalla RK, Balooch G, et al. (2006) Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice. J Bone Miner Res 21: 466-476.
95. Yao W, Cheng Z, Busse C, Pham A, Nakamura MC, et al. (2008) Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: A longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. Arthritis Rheum 58: 1674-1686.
96. Yao W, Cheng Z, Pham A, Busse C, Zimmermann EA, et al. (2008) Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization. Arthritis Rheum 58: 3485-3497.
97. Cao JJ, Kurimoto P, Boudignon B, Rosen C, Lima F, et al. (2007) Aging impairs IGF-I receptor activation and induces skeletal resistance to IGF-I. JBone Miner Res 22: 1271-1279.